Abstract:
Background: CKD is a progressive disorder that is commonly associated with hematological abnormalities.
Objective: Te objective of the study was to evaluate the role of hematological biomarkers in predicting CKD progression and
related complications in adult patients.
Methods: Te retrospective cross-sectional study evaluated hematological parameters such as hemoglobin, RBC, WBC, platelet,
and NLR; comorbidities; and CKD stages were recorded for analysis. Statistical analysis methods used included ANOVA, Chi
square, multiple logistic regression, Pearson correlation analyses, and ROC curve analysis. Te study was conducted under strict
adherence to the principles and guidelines of the Helsinki Declaration (2013).
Results: Te mean age was 56.2±14.8years, with males being 56.7%. About 70.8% of the patients were in CKD Stages 3–5.
Anemia was observed in 74.2% of the patients, whose prevalence increased alongside the increase in severity of CKD (p<0.001).
Tere was a signifcant decrease in hemoglobin, RBC, and platelet counts with advancing CKD stages, whereas WBC and NLR
increased (p<0.001). Hemoglobin (OR: 0.72; p<0.001), NLR(OR:1.43; p � 0.006),andplatelet count(OR:0.98; p � 0.021)were
independent predictors of progression to CKD Stage 5. ROC analysis yielded good results for hemoglobin (AUC: 0.81) and NLR
(AUC: 0.76) in predicting CKD Stage 5. Hemoglobin and platelet-count levels were signifcantly correlated with eGFR (r�−0.70
and r�0.58, respectively).
Conclusion: Te performance of hematological biomarkers, mainly hemoglobin and NLR, emerges as reliable predictor of CKD
progression and complications. Teir assessment as part of the CKD workup may then enhance risk stratifcation and early
intervention
